Nivolumab +/- ipilimumab in pts with advanced (adv)/metastatic chemothera py-refractory (CTx-R) gastric (G), esophageal (E), or gastroesophageal junction (GEJ) cancer: CheckMate 032 study / Ascierto, P. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - 35:(2017). [10.1200/JCO.2017.35.15_suppl.4014]

Nivolumab +/- ipilimumab in pts with advanced (adv)/metastatic chemothera py-refractory (CTx-R) gastric (G), esophageal (E), or gastroesophageal junction (GEJ) cancer: CheckMate 032 study

Ascierto P
2017

2017
Nivolumab +/- ipilimumab in pts with advanced (adv)/metastatic chemothera py-refractory (CTx-R) gastric (G), esophageal (E), or gastroesophageal junction (GEJ) cancer: CheckMate 032 study / Ascierto, P. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - 35:(2017). [10.1200/JCO.2017.35.15_suppl.4014]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/1014341
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 76
  • ???jsp.display-item.citation.isi??? ND
social impact